Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

BACKGROUND: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued. Fingolimod is seen as an alternative, but there are no long-term analyses of the effi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ther Adv Neurol Disord
Autori principali: Diem, Lara, Nedeltchev, Krassen, Kahles, Timo, Achtnichts, Lutz, Findling, Oliver
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6088480/
https://ncbi.nlm.nih.gov/pubmed/30116299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286418791103
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi